In 2024, the trade exchange (includes international purchases and sales) of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes was US$2.7B.
In 2024, the states with the most international sales in Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were Estado de México (US$50.5M), Jalisco (US$39M), Ciudad de México (US$33.2M), Baja California (US$16M), and Chihuahua (US$634k).
The states with the most international purchases in 2024 were Ciudad de México (US$2.17B), Estado de México (US$311M), Jalisco (US$42.4M), Baja California (US$8.92M), and Querétaro (US$5.82M).
In 2024, the main commercial destinations of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were France (US$55.9M), United States (US$28.2M), Belgium (US$8.25M), Guatemala (US$7.71M), and Colombia (US$5.56M).
The main commercial origins of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2024 were United States (US$401M), Germany (US$389M), Puerto Rico (US$367M), Switzerland (US$295M), and France (US$229M).
In the global context, the main exporting countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes in 2022 were Ireland (US$47.3B), United States (US$46.8B), and Belgium (US$46.5B). In the same year, the main importing countries of Other Blood Fractions and Immunological Products, whether or not Modified or Obtained by Biotechnological Processes were United States (US$67.8B), Germany (US$40.9B), and Belgium (US$21.6B).